SPOTLIGHT: FDA OKs Prezista

The FDA has approved Tibotec Pharmaceuticals' Prezista for treatment-resistant HIV patients. "One of the greatest challenges in HIV care is finding therapies for treatment-experienced patients," said Michael S. Saag, M.D., director of the AIDS Outpatient Clinic and the University of Alabama at Birmingham Center for AIDS Research. "This is an important new option for the thousands of people with HIV in the United States who are resistant to more than one protease inhibitor." Release

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.